The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma

E. Pozsgai, Andrew V Schally, G. Halmos, F. Rick, S. Bellyei

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Glioblastoma multiforme is the most common and most aggressive type of high grade tumor with a poor prognosis upon discovery. Based on earlier promising results earned with AN-162, a doxorubicin molecule linked to somatostatin (SST) analogue RC-160, it was our aim to determine the effect of AN-162 on DBTRG-05 glioblastoma cell line, and to test its efficacy in experimental brain tumors. We detected the expression of mRNA for somatostatin receptor (SSTR) subtypes 2 and 3 in DBTRG-05 cells with RT-PCR. Using ligand competition assay, specific high affinity receptors for somatostatin were found. The MTT assay showed that both AN-162 and doxorubicin (DOX) significantly inhibited cell proliferation and that there was no significant difference between the effects in vitro. Nude mice were xenografted with DBTRG-05 glioblastoma tumors. AN-162 showed a significant inhibition of tumor growth compared with the control group and the groups treated with equimolar doses of doxorubicin, somatostatin analogue RC-160, or the unconjugated mixture of doxorubicin plus RC-160. The tumor doubling time in the group of animals treated with AN-162 was extended and was significantly different from doubling times in the control group and in the other treatment groups. Our study clearly demonstrates a potent inhibitory effect of AN-162 in experimental glioblastoma, thus suggesting the possibility of its utilization in patients suffering from malignant brain cancer.

Original languageEnglish
Pages (from-to)781-786
Number of pages6
JournalHormone and Metabolic Research
Volume42
Issue number11
DOIs
StatePublished - Oct 11 2010

Fingerprint

Glioblastoma
Somatostatin
Tumors
Doxorubicin
Somatostatin Receptors
Brain Neoplasms
Assays
Brain
Neoplasms
Control Groups
Cell proliferation
Nude Mice
N-(2-diethylaminoethyl)-N-(2-hydroxy-2-phenylethyl)-2,5-dichloroaniline
Animals
Cells
Cell Proliferation
Ligands
Cell Line
Polymerase Chain Reaction
Messenger RNA

Keywords

  • AN-162
  • doxorubicine
  • glioblastoma
  • somatostatin
  • targeted therapy

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma. / Pozsgai, E.; Schally, Andrew V; Halmos, G.; Rick, F.; Bellyei, S.

In: Hormone and Metabolic Research, Vol. 42, No. 11, 11.10.2010, p. 781-786.

Research output: Contribution to journalArticle

@article{dff73736eb554cd3a1c582445dc55273,
title = "The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma",
abstract = "Glioblastoma multiforme is the most common and most aggressive type of high grade tumor with a poor prognosis upon discovery. Based on earlier promising results earned with AN-162, a doxorubicin molecule linked to somatostatin (SST) analogue RC-160, it was our aim to determine the effect of AN-162 on DBTRG-05 glioblastoma cell line, and to test its efficacy in experimental brain tumors. We detected the expression of mRNA for somatostatin receptor (SSTR) subtypes 2 and 3 in DBTRG-05 cells with RT-PCR. Using ligand competition assay, specific high affinity receptors for somatostatin were found. The MTT assay showed that both AN-162 and doxorubicin (DOX) significantly inhibited cell proliferation and that there was no significant difference between the effects in vitro. Nude mice were xenografted with DBTRG-05 glioblastoma tumors. AN-162 showed a significant inhibition of tumor growth compared with the control group and the groups treated with equimolar doses of doxorubicin, somatostatin analogue RC-160, or the unconjugated mixture of doxorubicin plus RC-160. The tumor doubling time in the group of animals treated with AN-162 was extended and was significantly different from doubling times in the control group and in the other treatment groups. Our study clearly demonstrates a potent inhibitory effect of AN-162 in experimental glioblastoma, thus suggesting the possibility of its utilization in patients suffering from malignant brain cancer.",
keywords = "AN-162, doxorubicine, glioblastoma, somatostatin, targeted therapy",
author = "E. Pozsgai and Schally, {Andrew V} and G. Halmos and F. Rick and S. Bellyei",
year = "2010",
month = "10",
day = "11",
doi = "10.1055/s-0030-1261955",
language = "English",
volume = "42",
pages = "781--786",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "11",

}

TY - JOUR

T1 - The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma

AU - Pozsgai, E.

AU - Schally, Andrew V

AU - Halmos, G.

AU - Rick, F.

AU - Bellyei, S.

PY - 2010/10/11

Y1 - 2010/10/11

N2 - Glioblastoma multiforme is the most common and most aggressive type of high grade tumor with a poor prognosis upon discovery. Based on earlier promising results earned with AN-162, a doxorubicin molecule linked to somatostatin (SST) analogue RC-160, it was our aim to determine the effect of AN-162 on DBTRG-05 glioblastoma cell line, and to test its efficacy in experimental brain tumors. We detected the expression of mRNA for somatostatin receptor (SSTR) subtypes 2 and 3 in DBTRG-05 cells with RT-PCR. Using ligand competition assay, specific high affinity receptors for somatostatin were found. The MTT assay showed that both AN-162 and doxorubicin (DOX) significantly inhibited cell proliferation and that there was no significant difference between the effects in vitro. Nude mice were xenografted with DBTRG-05 glioblastoma tumors. AN-162 showed a significant inhibition of tumor growth compared with the control group and the groups treated with equimolar doses of doxorubicin, somatostatin analogue RC-160, or the unconjugated mixture of doxorubicin plus RC-160. The tumor doubling time in the group of animals treated with AN-162 was extended and was significantly different from doubling times in the control group and in the other treatment groups. Our study clearly demonstrates a potent inhibitory effect of AN-162 in experimental glioblastoma, thus suggesting the possibility of its utilization in patients suffering from malignant brain cancer.

AB - Glioblastoma multiforme is the most common and most aggressive type of high grade tumor with a poor prognosis upon discovery. Based on earlier promising results earned with AN-162, a doxorubicin molecule linked to somatostatin (SST) analogue RC-160, it was our aim to determine the effect of AN-162 on DBTRG-05 glioblastoma cell line, and to test its efficacy in experimental brain tumors. We detected the expression of mRNA for somatostatin receptor (SSTR) subtypes 2 and 3 in DBTRG-05 cells with RT-PCR. Using ligand competition assay, specific high affinity receptors for somatostatin were found. The MTT assay showed that both AN-162 and doxorubicin (DOX) significantly inhibited cell proliferation and that there was no significant difference between the effects in vitro. Nude mice were xenografted with DBTRG-05 glioblastoma tumors. AN-162 showed a significant inhibition of tumor growth compared with the control group and the groups treated with equimolar doses of doxorubicin, somatostatin analogue RC-160, or the unconjugated mixture of doxorubicin plus RC-160. The tumor doubling time in the group of animals treated with AN-162 was extended and was significantly different from doubling times in the control group and in the other treatment groups. Our study clearly demonstrates a potent inhibitory effect of AN-162 in experimental glioblastoma, thus suggesting the possibility of its utilization in patients suffering from malignant brain cancer.

KW - AN-162

KW - doxorubicine

KW - glioblastoma

KW - somatostatin

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77957575775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957575775&partnerID=8YFLogxK

U2 - 10.1055/s-0030-1261955

DO - 10.1055/s-0030-1261955

M3 - Article

C2 - 20665426

AN - SCOPUS:77957575775

VL - 42

SP - 781

EP - 786

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 11

ER -